These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21544960)

  • 21. The serotonin-7 receptor as a novel therapeutic target.
    Stahl SM
    J Clin Psychiatry; 2010 Nov; 71(11):1414-5. PubMed ID: 21114946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
    Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
    Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain serotonin subsystem complexity and receptor heterogeneity: therapeutic potential of selective serotonin agonists and antagonists.
    Lesch KP; Aulakh CS; Murphy DL
    Psychopharmacol Ser; 1993; 10():52-69. PubMed ID: 8361982
    [No Abstract]   [Full Text] [Related]  

  • 24. Other 5-HT6 receptor-mediated effects.
    Borsini F
    Int Rev Neurobiol; 2011; 96():189-91. PubMed ID: 21329789
    [No Abstract]   [Full Text] [Related]  

  • 25. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.
    Rossé G; Schaffhauser H
    Curr Top Med Chem; 2010; 10(2):207-21. PubMed ID: 20166958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology.
    Marazziti D; Baroni S; Borsini F; Picchetti M; Vatteroni E; Falaschi V; Catena-Dell'Osso M
    Curr Med Chem; 2013; 20(3):371-7. PubMed ID: 23157629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease.
    Calhoun A; Ko J; Grossberg GT
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):101-105. PubMed ID: 28253832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New discoveries on antidepressive treatment: serotonin is the key].
    Evenden J
    Lakartidningen; 1997 Sep; 94(38):3262-6. PubMed ID: 9379793
    [No Abstract]   [Full Text] [Related]  

  • 29. The clinical utility of pharmacological agents that act at serotonin receptors.
    Peroutka SJ; Sleight AJ; McCarthy BG; Pierce PA; Schmidt AW; Hekmatpanah CR
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):253-62. PubMed ID: 2562495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational approaches to the design of novel 5-HT6 R ligands.
    Ivanenkov YA; Majouga AG; Veselov MS; Chufarova NV; Baranovsky SS; Filkov GI
    Rev Neurosci; 2014; 25(3):451-67. PubMed ID: 24867282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin syndrome from fluvoxamine and buspirone.
    Baetz M; Malcolm D
    Can J Psychiatry; 1995 Sep; 40(7):428-9. PubMed ID: 8548727
    [No Abstract]   [Full Text] [Related]  

  • 32. 5-HT6 receptor ligands as antidementia drugs.
    Mitchell ES
    Int Rev Neurobiol; 2011; 96():163-87. PubMed ID: 21329788
    [No Abstract]   [Full Text] [Related]  

  • 33. Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.
    Hayat F; Cho S; Rhim H; Indu Viswanath AN; Pae AN; Lee JY; Choo DJ; Choo HY
    Bioorg Med Chem; 2013 Sep; 21(17):5573-82. PubMed ID: 23810425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Top Med Chem; 2008; 8(12):1035-48. PubMed ID: 18691131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-HT3 receptors.
    Kilpatrick GJ; Bunce KT; Tyers MB
    Med Res Rev; 1990; 10(4):441-75. PubMed ID: 2243511
    [No Abstract]   [Full Text] [Related]  

  • 36. 5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.
    de Bruin NM; Kruse CG
    Curr Pharm Des; 2015; 21(26):3739-59. PubMed ID: 26044973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.
    Bromidge SM; Clarke SE; King FD; Lovell PJ; Newman H; Riley G; Routledge C; Serafinowska HT; Smith DR; Thomas DR
    Bioorg Med Chem Lett; 2002 May; 12(10):1357-60. PubMed ID: 11992776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1,2,3,4-tetrahydrocarbazoles as 5-HT6 serotonin receptor ligands.
    Chang-Fong J; Rangisetty JB; Dukat M; Setola V; Raffay T; Roth B; Glennon RA
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1961-4. PubMed ID: 15050637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple serotonin receptors: opportunities for new treatments for obesity?
    Dourish CT
    Obes Res; 1995 Nov; 3 Suppl 4():449S-462S. PubMed ID: 8697043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of 5-HT6 receptor ligands.
    Mancinelli A
    Int Rev Neurobiol; 2010; 94():153-72. PubMed ID: 21081206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.